← Back to Search

Radiation Therapy for B-Cell Lymphoma

N/A
Recruiting
Led By Chirayu Patel, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 months
Awards & highlights

Study Summary

This trial is studying if a new radiation therapy schedule will be better for people with relapsed/refractory B-cell lymphoma. It could reduce side effects and cost of treatment.

Who is the study for?
This trial is for adults over 18 with B-cell Lymphoma that's come back or hasn't responded to treatment, and who are set to undergo CAR T-cell therapy. They should be able to lay still for the duration of radiation sessions and not have conditions interfering with the study.Check my eligibility
What is being tested?
The study tests a new weekly schedule of Adaptive Bridging Radiation Therapy (ABRT) over five weeks before CAR T-cell therapy in patients with relapsed/refractory B-cell Lymphoma, aiming to improve side effects, time, cost, and effectiveness.See study design
What are the potential side effects?
Potential side effects may include typical reactions from radiation such as skin irritation at the site of treatment, fatigue, nausea, and other symptoms depending on which areas are being targeted by ABRT.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility: Percent of patients able to undergo ABRT
Secondary outcome measures
Adverse Events
Objective Response Rate (ORR)

Trial Design

1Treatment groups
Experimental Treatment
Group I: 5-5-5 Adaptive Bridging Radiation Therapy (ABRT)Experimental Treatment1 Intervention
5 Gy of adaptive radiation delivered every 5 business days (1 week apart) for up to 5 weeks prior to CAR T-cell therapy infusion

Find a Location

Who is running the clinical trial?

Varian Medical SystemsIndustry Sponsor
59 Previous Clinical Trials
3,769 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,934 Previous Clinical Trials
13,198,571 Total Patients Enrolled
Chirayu Patel, MDPrincipal InvestigatorMassachusetts General Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research effort still open to accepting participants?

"Per information found on clinicaltrials.gov, this particular trial is not open to new participants. The initial posting was dated February 14th 2024 and the last update took place August 29th 2023. Even though enrolment has closed for this medical study, 1797 other trials are actively recruiting patients across the USA."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Chirayu Patel 2024. "Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06004167.
~4 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top